WO2007137387A1 - Dietary supplement having improved efficacy at time of consumption - Google Patents
Dietary supplement having improved efficacy at time of consumption Download PDFInfo
- Publication number
- WO2007137387A1 WO2007137387A1 PCT/CA2006/000874 CA2006000874W WO2007137387A1 WO 2007137387 A1 WO2007137387 A1 WO 2007137387A1 CA 2006000874 W CA2006000874 W CA 2006000874W WO 2007137387 A1 WO2007137387 A1 WO 2007137387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- creatine
- dietary supplement
- compartment
- ingredient
- aqueous medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
Definitions
- the present invention relates to a dietary supplement, e.g., ready-to- drink supplements that include ingredients, e.g., creatine and derivatives thereof, which may be unstable if dissolved in an aqueous solution significantly before the dietary supplement is to be consumed.
- ingredients e.g., creatine and derivatives thereof
- the present invention may improve the efficacy of the ingredient at the time of consumption.
- a dietary supplement that includes a container having a first compartment and a second compartment.
- the first compartment includes an aqueous medium.
- the second compartment includes an ingredient that is stable when stored within the second compartment.
- the container is configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the ingredient of the second compartment is mixed with the aqueous medium of the first compartment.
- the ingredient which may be creatine or a derivative thereof, is less stable after being mixed with the aqueous medium of the first compartment.
- a dietary supplement that is provided in a container.
- a first compartment of the container includes an aqueous medium.
- a second compartment of the container includes at least one ingredient.
- the ingredient may be more stable when stored separately from the aqueous solution as compared to when dissolved in the aqueous solution.
- the first and second compartments are not in communication with each other.
- the first and second compartments are in communication with each other and the ingredient is mixed with the aqueous medium.
- an ingredient of a dietary supplement may be provided to a user is by suspending or dissolving the ingredient in an aqueous solution. While some dietary supplements may provide an ingredient pre- mixed in the aqueous solution, there are some ingredients (for example, creatine and others discussed in greater detail below) for which the suspension or dissolution of the ingredient within a solution for longer than a given period of time may undesirably alter, e.g., degrade or otherwise transform, the ingredient's molecular make-up and thus adversely effect the ingredient's function.
- ingredients for example, creatine and others discussed in greater detail below
- the present invention may improve the stability and/or efficacy of certain active ingredients by storing such ingredients in separate compartments of a single container.
- the separate compartments provide, prior to the consumption of the supplement, a physical barrier between the components of the dietary supplement, e.g., between the aqueous solution and the ingredient that may exhibit compromised stability and/or efficacy upon being, or within a given amount of time after being, dissolved in the aqueous solution.
- a user may selectively cause the contents of the separate compartments to mix. For example, the user may deform or otherwise manipulate the two compartments such that the ingredient stored in a first compartment is mixed with the aqueous solution in the second compartment. Since the user may perform this step, e.g., mixing the ingredient stored in the first compartment with the aqueous solution in the second compartment, at the time that the dietary supplement is to be consumed, any instability and/or inefficacy which may have resulted from the ingredient being dissolved in an aqueous solution for longer than a given period of time may be avoided.
- отно ⁇ ески ⁇ иили от ⁇ ество may include creatine also know as (alpha-methyl) guandino-acetic acid.
- Creatine is one of the basic molecules involved with energy storage, particularly in fast twitch glycolytic fibres. Creatine loading is known to increase the creatine stored within muscle tissue. Moreover, creatine is able to reversibly bind phosphate. Therefore, if more creatine is present within a muscle tissue, there is more stored and donatable phosphate within the muscle tissue. When a muscle undergoes a contraction, it employs adenosine triphosphate (ATP) as an energy source.
- ATP adenosine triphosphate
- a phosphate group is cleaved from ATP leaving the molecule adenosine diphosphate (ADP), which is devoid of energetic properties with respect to muscular contraction (Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 8 th Ed. Addison Wesley Longman, Inc. Don Mills, ON. 1996).
- Creatine is able to pick-up a phosphate and reversibly bind it; forming Phospho-creatine.
- Phospho-creatine ultimately donates a phosphate to ADP, thus rendering ATP, which is able to be used in a subsequent muscular contraction immediately following intense muscle effort and provides enough energy for 15 seconds of maximal contraction.
- creatine loading aids in the regeneration of ATP, leading to an increase in muscular output ability.
- Creatine converts to creatinine via an irreversible, pH-dependent, non- enzymatic reaction in aqueous medium.
- Aqueous and alkaline solutions contain a mixture of creatine and creatinine. In acidic solutions, 100% of creatine is converted to creatinine.
- creatine plays an important role in storing high energy phosphate for muscle use, creatinine is inactive and is excreted by the kidneys (Mesa JL, Ruiz JR, Gonzalez-Gross MM, Gutierrez Sainz A, Castillo Garzon MJ, Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32(14):903-44. Review.).
- Creatine is also known as 2-(carbamimidoyl-methyl-amino) acetic acid, N-(aminoiminomethyl)-N-methylglycine, N-amidinosarcosine, (alpha- methylguanido) acetic acid, N-methyl-N-guanylgliycine and methylglycocyamine.
- Creatine as used herein may refer to creatine in any of its known forms, e.g., salts and/or esters thereof.
- creatine in its various forms include but are not limited to creatine monohydrate, creatine alpha ketoglutarate, creatine ethyl ester HCI, tricreatine hydroxycitrate, creatine citrate, creatine pyruvate, creatine pyroglutamate, dicreatine malate, creatine anhydrous, creatine taurinate, and creatine methyl ester.
- Tricreatine hydroxycitrate is another example of a creatine derivative which may be unstable in an aqueous medium. It is formed in an anionic- cationic reaction whereby three moles of creatine are bound to one mole of hydroxycitric acid.
- the present invention in accordance with various embodiments thereof, involves a dietary supplement that is disposed in a container that has at least two compartments.
- the ingredient may be maintained in a first compartment of the container until a user selectively causes, e.g., immediately prior to consumption, the ingredient to be mixed with an aqueous solution stored in a second compartment of the container.
- U.S. Patent No. 2,562,402 discloses a two compartment container wherein the outer container is comprised of a flexible material which upon squeezing increases the internal pressure.
- the inner container or capsule is pressure-sensitive and upon an increase in the internal pressure of the outer container, the inner capsule ruptures and its contents are mixed with the contents of the outer container.
- U.S. Patent No. 2,753,990 discloses a glass container having large and small-sized, separate compartments for the storage of the first and second liquids in the separate storage compartments. When the large compartment is opened, thus resulting in a drop in pressure below that of the small compartment leads to the opening of a valve in the wall separating the two compartments allowing for the mixing of the liquids in the two compartments.
- U.S. Patent No. 4,627,986 discloses a container for the storage of a pressurized fluid, having a separate compartment therein for the segregated storage of a second material. The mechanism is arranged such that it is sensitive to the rapid drop in pressure upon the opening of the container and that the contents of the segregated container are released into the fluid of the first container.
- U.S. Patent No. 6,620,444 discloses a two compartment container under pressure wherein the inner compartment opens in response to pressure change upon the opening of the outer compartment. The contents of the inner container are thus released and mixed with the contents of the outer container immediately prior to consumption.
- Examples 1 to 4 below illustrate some of the dietary supplements that may advantageously employ such containers.
- these dietary supplements include active ingredients that may irreversibly convert to inactive forms of the ingredient were the ingredients to be dissolved in the respective aqueous solution greater than a given period of time prior to a user consuming the dietary supplement.
- the stability and/or efficacy of the ingredients may be increased by preventing the active molecules from dissolving or being suspended in the aqueous solution until a predetermined time period, e.g., immediately, prior to consumption.
- a dietary supplement is contained within a container comprising two compartments.
- a solute mixture of granular anhydrous creatine (2.5000 g), calcium salt of ketoisocaproic acid (0.0500 g), and trometamol salt of alpha lipoic acid (0.1000 g) is contained within a container comprising two compartments.
- a solute mixture of granular anhydrous creatine (2.5000 g), calcium salt of ketoisocaproic acid (0.0500 g), and trometamol salt of alpha lipoic acid (0.1000 g) is contained within a second compartment.
- a solvent is contained.
- the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
- a dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture of creatine citrate
- trometamol salt of alpha lipoic acid 0.0510 g
- creatine alpha ketoglutarate 0.0010 g
- creatine ethyl ester HCI 0.0010 g
- creatine methyl ester 0.0010 g
- dicreatine malate 0.0010 g
- a dietary supplement is contained within a container comprising two compartments.
- a solvent is contained within a second compartment.
- the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
- Example 4 A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture comprising at least tricreatine hydroxycitric acid or a derivative thereof is contained. Within a second compartment, a solvent is contained. At the time of opening the two- compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A dietary supplement provided in a container, wherein the container comprises a first compartment and a second compartment. The first compartment includes an aqueous medium. The second compartment includes the dietary supplement that is stable when stored within the second compartment, the container is configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the dietary supplement of the second compartment is mixed with the aqueous medium of the first compartment. The dietary supplement, which may be creatine or a derivative thereof, is less stable after being mixed with the aqueous medium of the first compartment.
Description
Dietary Supplement Having Improved Efficacy at Time of Consumption
Field of the Invention
The present invention relates to a dietary supplement, e.g., ready-to- drink supplements that include ingredients, e.g., creatine and derivatives thereof, which may be unstable if dissolved in an aqueous solution significantly before the dietary supplement is to be consumed. By improving the stability of such ingredients, the present invention may improve the efficacy of the ingredient at the time of consumption.
Summary of the Invention
According to an embodiment of the present invention, there is provided a dietary supplement that includes a container having a first compartment and a second compartment. The first compartment includes an aqueous medium. The second compartment includes an ingredient that is stable when stored within the second compartment. The container is configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the ingredient of the second compartment is mixed with the aqueous medium of the first compartment. The ingredient, which may be creatine or a derivative thereof, is less stable after being mixed with the aqueous medium of the first compartment.
According to another embodiment of the present invention, there is provided a dietary supplement that is provided in a container. A first compartment of the container includes an aqueous medium. A second compartment of the container includes at least one ingredient. The ingredient
may be more stable when stored separately from the aqueous solution as compared to when dissolved in the aqueous solution. In a pre-use configuration of the container, the first and second compartments are not in communication with each other. In a use configuration of the container, e.g., immediately prior to consumption of the dietary supplement by a user, the first and second compartments are in communication with each other and the ingredient is mixed with the aqueous medium.
Detailed Description of the Invention One of the ways that an ingredient of a dietary supplement may be provided to a user is by suspending or dissolving the ingredient in an aqueous solution. While some dietary supplements may provide an ingredient pre- mixed in the aqueous solution, there are some ingredients (for example, creatine and others discussed in greater detail below) for which the suspension or dissolution of the ingredient within a solution for longer than a given period of time may undesirably alter, e.g., degrade or otherwise transform, the ingredient's molecular make-up and thus adversely effect the ingredient's function. Since the stability and/or efficacy of certain ingredients of a dietary supplement formulation can be compromised within a given amount of time after being dissolved in an aqueous solution, the present invention may improve the stability and/or efficacy of certain active ingredients by storing such ingredients in separate compartments of a single container. The separate compartments provide, prior to the consumption of the supplement, a physical barrier between the components of the dietary supplement, e.g., between the aqueous solution and the ingredient that may
exhibit compromised stability and/or efficacy upon being, or within a given amount of time after being, dissolved in the aqueous solution.
To consume the supplement, a user may selectively cause the contents of the separate compartments to mix. For example, the user may deform or otherwise manipulate the two compartments such that the ingredient stored in a first compartment is mixed with the aqueous solution in the second compartment. Since the user may perform this step, e.g., mixing the ingredient stored in the first compartment with the aqueous solution in the second compartment, at the time that the dietary supplement is to be consumed, any instability and/or inefficacy which may have resulted from the ingredient being dissolved in an aqueous solution for longer than a given period of time may be avoided.
Various embodiments of the present invention may include creatine also know as (alpha-methyl) guandino-acetic acid. Creatine is one of the basic molecules involved with energy storage, particularly in fast twitch glycolytic fibres. Creatine loading is known to increase the creatine stored within muscle tissue. Moreover, creatine is able to reversibly bind phosphate. Therefore, if more creatine is present within a muscle tissue, there is more stored and donatable phosphate within the muscle tissue. When a muscle undergoes a contraction, it employs adenosine triphosphate (ATP) as an energy source. During this process a phosphate group is cleaved from ATP leaving the molecule adenosine diphosphate (ADP), which is devoid of energetic properties with respect to muscular contraction (Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 8th Ed. Addison Wesley Longman, Inc. Don Mills, ON. 1996). Creatine is able to pick-up a phosphate
and reversibly bind it; forming Phospho-creatine. Phospho-creatine ultimately donates a phosphate to ADP, thus rendering ATP, which is able to be used in a subsequent muscular contraction immediately following intense muscle effort and provides enough energy for 15 seconds of maximal contraction. Therefore, creatine loading aids in the regeneration of ATP, leading to an increase in muscular output ability. (Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 8th Ed. Addison Wesley Longman, Inc. Don Mills, ON. 1996).
Creatine converts to creatinine via an irreversible, pH-dependent, non- enzymatic reaction in aqueous medium. Aqueous and alkaline solutions contain a mixture of creatine and creatinine. In acidic solutions, 100% of creatine is converted to creatinine. While creatine plays an important role in storing high energy phosphate for muscle use, creatinine is inactive and is excreted by the kidneys (Mesa JL, Ruiz JR, Gonzalez-Gross MM, Gutierrez Sainz A, Castillo Garzon MJ, Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32(14):903-44. Review.).
Creatine is also known as 2-(carbamimidoyl-methyl-amino) acetic acid, N-(aminoiminomethyl)-N-methylglycine, N-amidinosarcosine, (alpha- methylguanido) acetic acid, N-methyl-N-guanylgliycine and methylglycocyamine. Creatine as used herein may refer to creatine in any of its known forms, e.g., salts and/or esters thereof. Examples of creatine in its various forms include but are not limited to creatine monohydrate, creatine alpha ketoglutarate, creatine ethyl ester HCI, tricreatine hydroxycitrate,
creatine citrate, creatine pyruvate, creatine pyroglutamate, dicreatine malate, creatine anhydrous, creatine taurinate, and creatine methyl ester.
Tricreatine hydroxycitrate is another example of a creatine derivative which may be unstable in an aqueous medium. It is formed in an anionic- cationic reaction whereby three moles of creatine are bound to one mole of hydroxycitric acid. Applicant's co-pending U.S. Patent Application No. 11/349,960, for "Creatine Hydroxycitric Acid Salts and Methods for Their Production and Use in Individuals", which was filed on February 7, 2006, and which is based upon U.S. Provisional Patent No. 60/651 ,049, filed on February 7, 2005, discloses a method for producing tricreatine hydroxycitrate.
As set forth above, the present invention, in accordance with various embodiments thereof, involves a dietary supplement that is disposed in a container that has at least two compartments. In order to improve the stability and/or efficacy of an ingredient of the dietary supplement, the ingredient may be maintained in a first compartment of the container until a user selectively causes, e.g., immediately prior to consumption, the ingredient to be mixed with an aqueous solution stored in a second compartment of the container.
While the present invention envisions that any type of multi- compartmented container may be employed, some examples of two-part beverage containers are disclosed, for example, in U.S. Patent Nos. 2,562,402, 2,753,990, 4,627,986 and 6,620,444.
U.S. Patent No. 2,562,402, discloses a two compartment container wherein the outer container is comprised of a flexible material which upon squeezing increases the internal pressure. The inner container or capsule is pressure-sensitive and upon an increase in the internal pressure of the outer
container, the inner capsule ruptures and its contents are mixed with the contents of the outer container.
U.S. Patent No. 2,753,990, discloses a glass container having large and small-sized, separate compartments for the storage of the first and second liquids in the separate storage compartments. When the large compartment is opened, thus resulting in a drop in pressure below that of the small compartment leads to the opening of a valve in the wall separating the two compartments allowing for the mixing of the liquids in the two compartments. U.S. Patent No. 4,627,986, discloses a container for the storage of a pressurized fluid, having a separate compartment therein for the segregated storage of a second material. The mechanism is arranged such that it is sensitive to the rapid drop in pressure upon the opening of the container and that the contents of the segregated container are released into the fluid of the first container.
U.S. Patent No. 6,620,444, discloses a two compartment container under pressure wherein the inner compartment opens in response to pressure change upon the opening of the outer compartment. The contents of the inner container are thus released and mixed with the contents of the outer container immediately prior to consumption.
While the preceding examples illustrate some of the types of containers that may be employed in the practice of the present invention, Examples 1 to 4 below illustrate some of the dietary supplements that may advantageously employ such containers. Generally, these dietary supplements include active ingredients that may irreversibly convert to inactive forms of the ingredient
were the ingredients to be dissolved in the respective aqueous solution greater than a given period of time prior to a user consuming the dietary supplement. In this manner, the stability and/or efficacy of the ingredients may be increased by preventing the active molecules from dissolving or being suspended in the aqueous solution until a predetermined time period, e.g., immediately, prior to consumption.
Although the following examples illustrate the practice of the present invention in five of its embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and the following examples.
EXAMPLES Example 1
A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture of granular anhydrous creatine (2.5000 g), calcium salt of ketoisocaproic acid (0.0500 g), and trometamol salt of alpha lipoic acid (0.1000 g) is contained. Within a second compartment, a solvent is contained. At the time of opening the two- compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
Example 2
A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture of creatine citrate
(5.0170 g), trometamol salt of alpha lipoic acid (0.0510 g), creatine alpha ketoglutarate (0.0010 g), creatine ethyl ester HCI (0.0010 g), creatine methyl ester (0.0010 g), dicreatine malate (0.0010 g), granular anhydrous creatine
(0.00094 g), calcium salt of ketoisocaproic acid (0.00002 g) is contained. Within a second compartment, a solvent is contained. At the time of opening the two-compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
Example 3
A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture of creatine citrate (4.9940 g), trometamol salt of alpha lipoic acid (0.0510 g), granular anhydrous creatine (0.00094 g), calcium salt of ketoisocaproic acid (0.00002 g), creatine alpha ketoglutarate (0.0010 g), creatine pyroglutamate (0.0010 g), dicreatine malate (0.0010 g), L-glutamine (0.0010 g), and taurine (0.0010 g) is contained. Within a second compartment, a solvent is contained. At the time of opening the two-compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
Example 4 A dietary supplement is contained within a container comprising two compartments. Within a first compartment, a solute mixture comprising at least tricreatine hydroxycitric acid or a derivative thereof is contained. Within a second compartment, a solvent is contained. At the time of opening the two- compartment container, the contents of the first compartment are emptied, e.g., automatically, into the second compartment such that the solutes contained within the first compartment are combined with the solvent in the second compartment to form a consumable solution.
Claims
1. A dietary supplement comprising: a container having a first compartment and a second compartment, the first compartment including an aqueous medium, the second compartment including an ingredient that is stable when stored within the second compartment, the container being configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the ingredient of the second compartment is mixed with the aqueous medium of the first compartment, the ingredient being less stable after being mixed with the aqueous medium of the first compartment.
2. The dietary supplement of claim 1 , wherein the ingredient is creatine or a derivative thereof.
3. The dietary supplement of claim 2, wherein the creatine or a derivative thereof comprises at least one of creatine monohydrate, creatine alpha ketoglutarate, creatine ethyl ester HCI, tricreatine hydroxycitrate, creatine citrate, creatine pyruvate, creatine pyroglutamate, dicreatine malate, creatine anhydrous, creatine taurinate, creatine lipoate and creatine methyl ester.
4. The dietary supplement of claim 1 , wherein the second compartment comprises a mixture of granular anhydrous creatine, calcium salt of ketoisocaproic acid, and trometamol salt of alpha lipoic acid.
5. The dietary supplement of claim 4, wherein the mixture includes about 2.5g of granular anhydrous creatine, about 0.05g of calcium salt of ketoisocaproic acid, and about 0.1g of trometamol salt of alpha lipoic acid.
6. The dietary supplement of claim 1 , wherein the second compartment comprises a mixture of creatine citrate, trometamol salt of alpha lipoic acid, creatine alpha ketoglutarate, creatine ethyl ester HCI, creatine methyl ester, dicreatine malate, granular anhydrous creatine, calcium salt of ketoisocaproic acid.
7. The dietary supplement of claim 6, wherein the mixture includes about 5.0170 g of creatine citrate, about 0.0510 g of trometamol salt of alpha lipoic acid, about 0.0010 g of creatine alpha ketoglutarate, about 0.0010 g of creatine ethyl ester HCI, about 0.001Og of creatine methyl ester, about 0.001 Og of dicreatine malate, about 0.00094g of granular anhydrous creatine, about 0.00002 g of calcium salt of ketoisocaproic acid.
8. The dietary supplement of claim 1 , wherein the second compartment comprises a mixture of creatine citrate, trometamol salt of alpha lipoic acid, granular anhydrous creatine, calcium salt of ketoisocaproic acid, creatine alpha ketoglutarate, creatine pyroglutamate, dicreatine malate, L-glutamine, and taurine.
9. The dietary supplement of claim 8, wherein the mixture includes about 4.994g of creatine citrate, about 0.051Og of trometamol salt of alpha lipoic acid, about 0.00094g of granular anhydrous creatine, about 0.0002g of calcium salt of ketoisocaproic acid, about 0.001 Og of creatine alpha ketoglutarate, about 0.001Og of creatine pyroglutamate, about 0.001Og of dicreatine malate, about 0.001 Og of L-glutamine and about 0.001 Og of taurine.
10. A dietary supplement that is provided in a container, comprising: a first compartment of the container including an aqueous medium; and a second compartment of the container including an ingredient, the ingredient being more stable when stored separately from the aqueous solution as compared to when dissolved in the aqueous solution, wherein, in a pre-use configuration of the container, the first and second compartments are not in communication with each other, and wherein, in a use configuration of the container, the first and second compartments are in communication with each other and the ingredient is mixed with the aqueous medium.
11. The dietary supplement of claim 10, wherein the ingredient is creatine or a derivative thereof.
12. The dietary supplement of claim 11 , wherein the creatine or a derivative thereof comprises at least one of creatine monohydrate, creatine alpha ketoglutarate, creatine ethyl ester HCI, tricreatine hydroxycitrate, creatine citrate, creatine pyruvate, creatine pyroglutamate, dicreatine malate, creatine anhydrous, creatine taurinate, creatine lipoate and creatine methyl ester.
13. The dietary supplement of claim 10, wherein the second compartment comprises a mixture of granular anhydrous creatine, calcium salt of ketoisocaproic acid, and trometamol salt of alpha lipoic acid.
14. The dietary supplement of claim 13, wherein the mixture includes about 2.5g of granular anhydrous creatine, about 0.05g of calcium salt of ketoisocaproic acid, and about 0.1 g of trometamol salt of alpha lipoic acid.
15. The dietary supplement of claim 10, wherein the second compartment comprises a mixture of creatine citrate, trometamol salt of alpha lipoic acid, creatine alpha ketoglutarate, creatine ethyl ester HCI, creatine methyl ester, dicreatine malate, granular anhydrous creatine, calcium salt of ketoisocaproic acid.
16. The dietary supplement of claim 15, wherein the mixture includes about 5.0170 g of creatine citrate, about 0.0510 g of trometamol salt of alpha lipoic acid, about 0.0010 g of creatine alpha ketoglutarate, about 0.0010 g of creatine ethyl ester HCI, about 0.001Og of creatine methyl ester, about 0.001Og of dicreatine malate, about 0.00094g of granular anhydrous creatine, about 0.00002 g of calcium salt of ketoisocaproic acid.
17. The dietary supplement of claim 10, wherein the second compartment comprises a mixture of creatine citrate, trometamol salt of alpha lipoic acid, granular anhydrous creatine, calcium salt of ketoisocaproic acid, creatine alpha ketoglutarate, creatine pyroglutamate, dicreatine malate, L- glutamine, and taurine.
18. The dietary supplement of claim 17, wherein the mixture includes about 4.994g of creatine citrate, about 0.051 Og of trometamol salt of alpha lipoic acid, about 0.00094g of granular anhydrous creatine, about.0002g of calcium salt of ketoisocaproic acid, about 0.001Og of creatine alpha ketoglutarate, about 0.001Og of creatine pyroglutamate, about 0.001Og of dicreatine malate, about 0.001Og of L-glutamine and about 0.001 Og of taurine.
19. A dietary supplement according to claim 1 , wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution having a pH less than or equal to 7.
20. A dietary supplement according to claim 1 , wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution having a pH greater than or equal to 7.
21. A dietary supplement according to claim 1 , wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution being more acidic than the unstable ingredient.
22. A dietary supplement according to claim 1 , wherein the unstable ingredient is separated from an aqueous medium or solution being more basic than the unstable ingredient.
23. A dietary supplement according to claim 10, wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution having a pH less than or equal to 7.
24. A dietary supplement according to claim 10, wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution having a pH greater than or equal to 7.
25. A dietary supplement according to claim 10, wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution being more acidic than the unstable ingredient.
26. A dietary supplement according to claim 10, wherein the ingredient being more stable when stored separately from the aqueous medium or solution is separated from the aqueous medium or solution being more basic than the unstable ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2006/000874 WO2007137387A1 (en) | 2006-05-30 | 2006-05-30 | Dietary supplement having improved efficacy at time of consumption |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2006/000874 WO2007137387A1 (en) | 2006-05-30 | 2006-05-30 | Dietary supplement having improved efficacy at time of consumption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007137387A1 true WO2007137387A1 (en) | 2007-12-06 |
Family
ID=38778039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2006/000874 Ceased WO2007137387A1 (en) | 2006-05-30 | 2006-05-30 | Dietary supplement having improved efficacy at time of consumption |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007137387A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2562402A (en) * | 1949-04-05 | 1951-07-31 | Food Res Lab Inc | Dispensing unit for therapeutic agents |
| US2753990A (en) * | 1953-07-02 | 1956-07-10 | Chalfin Philip | Container |
| US4627986A (en) * | 1982-01-04 | 1986-12-09 | General Foods Corporation | Pressurized container providing for the separate storage of a plurality of materials |
| US6620444B1 (en) * | 1998-04-22 | 2003-09-16 | Schmalbach-Lubeca Ag | Two-compartment container for and method of admixing a flavour to a beverage |
-
2006
- 2006-05-30 WO PCT/CA2006/000874 patent/WO2007137387A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2562402A (en) * | 1949-04-05 | 1951-07-31 | Food Res Lab Inc | Dispensing unit for therapeutic agents |
| US2753990A (en) * | 1953-07-02 | 1956-07-10 | Chalfin Philip | Container |
| US4627986A (en) * | 1982-01-04 | 1986-12-09 | General Foods Corporation | Pressurized container providing for the separate storage of a plurality of materials |
| US6620444B1 (en) * | 1998-04-22 | 2003-09-16 | Schmalbach-Lubeca Ag | Two-compartment container for and method of admixing a flavour to a beverage |
Non-Patent Citations (1)
| Title |
|---|
| Retrieved from the Internet <URL:http://www.muscle-shop.co.uk/products/asp/prodID/203041/af/page.htm> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12448357B1 (en) | Amino acid compositions | |
| US5925378A (en) | Method for enhancing delivery and uniformity of concentration of cellular creatine | |
| Wu et al. | Alpha-ketoglutarate: physiological functions and applications | |
| US20090137670A1 (en) | Amino Acid Compounds | |
| CA2914514C (en) | A process for producing microcapsules comprising an active component encapsulated, protected and stabilised within a protein shell. | |
| JP2006510711A5 (en) | ||
| KR0143232B1 (en) | Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation | |
| US10646508B1 (en) | Method of safely administering nitrate dietary supplements and compositions | |
| US7786073B2 (en) | Container for dietary supplement having improved efficacy at time of consumption | |
| CA2548695C (en) | Dietary supplement having improved efficacy at time of consumption | |
| WO2007137387A1 (en) | Dietary supplement having improved efficacy at time of consumption | |
| US10435356B1 (en) | Amino acid compositions | |
| US20020131987A1 (en) | Method for enhancing stable cellular creatine concentration | |
| JP2002531392A (en) | Preparation and use of dry compositions that are soluble in the presence of water and prevent the Meyer reaction in the dry state | |
| Raghavendra Rao et al. | l‐[3H] Nitroarginine and l‐[3H] Arginine Uptake into Rat Cerebellar Synaptosomes: Kinetics and Pharmacology | |
| US10426792B1 (en) | Amino acid compositions | |
| US10426750B1 (en) | Amino acid supplement formulations | |
| US20080153897A1 (en) | Creatine pyroglutamic acid salts and methods for their production and use in individuals | |
| WO2012034201A2 (en) | Creatine-containing food supplement composition, method for preparing same and food supplement dosage form | |
| AU4954199A (en) | Method for enhancing stable cellular creatine concentration | |
| WO2009079739A1 (en) | The use of creatine pyroglutamicacid salt to facilitate increased neural health | |
| CA2612550A1 (en) | Creatine pyroglutamic acid salts and methods for their production and use in individuals | |
| US20250163000A1 (en) | Amino acid compositions | |
| Raj et al. | GLUTAMINE KINETICS AND PROTEIN TURNOVER IN END-STAGE RENAL | |
| ZA200110072B (en) | Method for enhancing stable cellular creatine concentration. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06752728 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12-03-2009) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06752728 Country of ref document: EP Kind code of ref document: A1 |